Moderna's mRNA Cancer Vaccine Success Raises Questions on Future Growth

Moderna's stock has surged 404% this year following a pivotal phase 3 trial success for its personalized mRNA cancer vaccine, but shares have pulled back from highs, raising questions about future upside. The trial showed intismeran autogene, developed with Merck, significantly improved recurrence-free survival in melanoma patients versus Keytruda alone, boosting confidence in Moderna's broader mRNA pipeline and sending shares up over 100% on the news. Despite the rally, Moderna trades at about $148, down from a $176.66 peak, with a $59 billion market cap and a high price-to-sales ratio of 27.5, though analysts see potential from its approved flu vaccine and a possible $5.6 billion peak revenue for the cancer vaccine.